Abstract:Huashan liver transplantation. Background: Introducing the experience of living donor liver transplantation in the treatment of inherited metabolic liver diseases. Materials and Methods: A retrospective analysis of 53 children with inherited metabolic diseases from April 2015 to September 2019 in our hospital was performed. The end-stage liver disease model (PELD) and type of transplant, postoperative complications and outcomes were analyzed. Results: There were 7 cases of Wilson disease, 7 cases of Alagille syndrome (AGS), and 19 cases of progressive familial intrahepatic cholestasis (PFIC). The remaining types of diseases included glycogen storage disease (GSD), urea cycle disorder (UCD), hyperbilirubinemia, and fulminant hepatic failure due to genetic defects. Among them, 11 cases received deceased donor liver transplantation (DDLT), the remaining all received living donor liver transplantation (LDLT). 5 cases of right lobe, 4 cases of left lobe, and the rest of left lateral lobe was donated in LDLT. The average donor age (31.57 ± 1.204) years old, 2 patients with bile leakage after surgery and cured by conservative treatment finally, long-term follow-up without any other complications. The recipients were all treated with a piggy-back transplantation, the median PELD score was 19 (range1-43) and a median age of 58.4 months (± 8.7 months). There were 3 cases of perioperative death, including 1 case of pulmonary infection, 1 case of postoperative pneumothorax, 1 case of primary non-function. One patient died of pulmonary infection after discharge from hospital, and the remaining recipients survived to the present day. Postoperative complications included 5 cases of pulmonary infection, 8 cases of biliary bile leakage or stenosis, 5 cases of EBV, CMV or hepatitis B infection, and 4 cases of chylous leakage. The cumulative survival rates of recipients at 1 year, 2 years, and 3 years were 92.5%, 92.5%, and 92.5%, respectively. The cumulative survival rates of grafts at 1 year, 2 years, and 3 years were 92.5%, 92.5% and 92.5%, respectively. Conclusion: Living donor liver transplantation can achieve a better prognosis in the treatment of genetic metabolic liver diseases, but how to reduce biliary complications and how to prevent lung infections and viral infections remains a problem.

Optimal transplant strategy of pediatric liver transplantation for fibropolycystic liver disease: Multicenter retrospective study in Japan

Current Status and Outcomes of Living Donor Liver Transplantation for Pediatric Acute Liver Failure: Results From a Multicenter Retrospective Study Over Two Decades

Living Donor Liver Transplantation in Treating Progressive Familiar Intrahepatic Cholestasis in Children

LIVER TRANSPLANTATION FOR THE TREATMENT OF CHILDREN WITH INHERITED METABOLIC LIVER DISEASES: SINGLE CENTER EXPERIENCE

Liver transplantation for fulminant hepatic failure in infancy: a single center experience.

Pediatric Liver Transplantation in 31 Consecutive Children

Long-term Results of Liver Transplantation for Polycystic Liver Disease: Single-center Experience in China

Living Donor Liver Transplantation in Children: Perioperative Risk Factors and a Nomogram for Prediction of Survival.

Marginal Parental Donors for Pediatric Living Donor Liver Transplantation

Liver transplantation for pediatric liver malignancies

Optimal introduction of laparoscopic liver resection for Child-Pugh B

Indications for liver transplantation in pediatric patients

Living donor liver transplantations for pediatric patients withbiliary atresia in a single center: 306

The Impact of Early Indication of Living Donor Liver Transplantation on the Outcomes of Patients With Propionic Acidemia: A Single‐Center Experience

Modified by the Innovative Drugs and Strategies—Pattern of Selected Indications for Pediatric Liver Transplantation

Improved survival of pediatric deceased donor liver transplantation recipients after introduction of the pediatric prioritization system: Analysis of data from a Japanese national survey

Adult living donor liver transplantation in Singapore: the Asian centre for liver diseases and transplantation experience

Long-Term Results of Pediatric Liver Transplantation for Progressive Familial Intrahepatic Cholestasis

The Therapeutic Effect of Living-Related Liver Transplantation for Children

Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria

Liver Transplantation for Pediatric Patients with Congenital Heart Disease: A Single-Center Study in Mainland China.